Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.

Date

28 Sep 2019

Session

Poster Display session 1

Topics

Clinical Research

Tumour Site

Presenters

Tina Gruosso

Citation

Annals of Oncology (2019) 30 (suppl_5): v159-v193. 10.1093/annonc/mdz244

Authors

T. Gruosso1, M. O’Connor2, J. Denis3, R. Figueredo4, J. Koropatnick4, G. Tremblay3, I.A. Tikhomirov5

Author affiliations

  • 1 Translationnal Research, Forbius, H2Y 2Z4 - Montreal/CA
  • 2 Research And Development, Forbius, H2Y 2Z4 - Montreal/CA
  • 3 Preclinical, Forbius, H2Y 2Z4 - Montreal/CA
  • 4 Lawson Health Research Institute, University of Western Ontario, N6C2R5 - London/CA
  • 5 Research And Development, Forbius, 78701 - Austin/US

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3582

Background

Resistance to immune checkpoint inhibitors (ICIs) is a major unmet medical need. The TGF-beta pathway is a key immunosuppressive mechanism that correlates with resistance to PD-1/PD-L1 inhibitors. TGF-beta acts by inhibiting the recruitment and activation of anti-tumor T-cells, either directly, or indirectly through its action on cancer-associated fibroblasts. AVID200 is a receptor ectodomain trap that was rationally-designed to inhibit with pM potency TGF-beta1 and -beta3, the principal oncogenic TGF-beta isoforms. Targeting these two isoforms with AVID200 has the potential to increase the number of patients that benefit from ICIs.

Methods

The percent of patients exhibiting tumor over-expression (>30FPKM) of TGF-beta isoforms was analyzed in > 10,000 samples from the CGA RNAseq data. The potency and selectivity of AVID200 and other clinical stage TGF-beta inhibitors was assessed using an A549 cell-based. The ability of AVID200 to enhance the tumor-cell killing activity of T-cells was evaluated in vivo in a syngeneic 4T1 cancer model. The ability of AVID200 to enhance T-cell infiltration and the efficacy of ICIs was assessed in EMT-6 and MC-38 cancer models.

Results

Gene expression analysis revealed that TGF-beta1 is the predominant isoform expressed in solid tumors, with TGF-beta3 also being expressed in multiple tumor types. This indicates that it is important to target both ligand isoforms for maximal efficacy, particularly because TGF-beta 1 and 3 can functionally substitute for each other. In vitro, AVID200 exhibited the best potency (low pM) and selectivity for TGF-beta 1 & 3 vs TGF-beta 2 amongst the TGF-beta inhibitors tested. Having minimal activity on TGF-beta2 is desirable because TGF-beta2 is involved in cardiac homeostasis and the positive regulation of hematopoiesis. In vivo, AVID200 was shown to promote T-cell infiltration and to increase the anti-tumor activity of ICIs.

Conclusions

In conclusion, AVID200 efficiently neutralizes TGF-beta 1 and 3, the main oncogenic isoforms, with best-in-class potency and sensitizes tumors to immune checkpoint blockade. The AVID200 Phase 1 study in patients with solid tumors is ongoing.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Forbius (Formation Biologics).

Funding

Forbius (Formation Biologics).

Disclosure

T. Gruosso: Full / Part-time employment: Forbius (Formation Biologics). M. O’Connor: Leadership role, Licensing / Royalties, Full / Part-time employment, Officer / Board of Directors: Forbius (Formation Biologics). J. Denis: Full / Part-time employment: Forbius (Formation Biologics). R. Figueredo: Research grant / Funding (self): Forbius (Formation Biologics); Research grant / Funding (self): Trillium Therapeutics, Inc.; Research grant / Funding (self): Critical Outcome Technologies, Inc. J. Koropatnick: Licensing / Royalties: Sarissa Inc; Research grant / Funding (self): Forbius (Formation Biologics); Research grant / Funding (self): Trillium Therapeutics, Inc; Research grant / Funding (self): Critical Outcome Technologies, Inc. G. Tremblay: Licensing / Royalties: Alethia Biotherapeutics; Full / Part-time employment: Forbius (Formation Biologics). I.A. Tikhomirov: Leadership role, Shareholder / Stockholder / Stock options, Licensing / Royalties, Full / Part-time employment, Officer / Board of Directors: Forbius (Formation Biologics).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.